AC Immune
AC Immune SA is a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and certain rare indications. The company focuses on pioneering science and technology platforms to discover, develop, and commercialize breakthrough therapies and diagnostics, aiming to make a significant impact on patients' lives through early diagnosis, targeted treatments, and prevention strategies. Their diversified pipeline includes immunotherapies, small molecules, and diagnostics targeting key pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43. The company collaborates with industry leaders like Takeda, Janssen, Lilly, and Life Molecular Imaging, and is committed to advancing treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.
Industries
Nr. of Employees
medium (51-250)
AC Immune
EPFL Innovation Park-Building B 1015 Lausanne / Switzerland
Patents
Products
Active immunotherapy candidates targeting amyloid-beta (clinical-stage)
Liposomal vaccine-type active immunotherapies designed to induce antibodies against pathological amyloid-beta species for prevention or treatment of Alzheimer’s disease, evaluated in early clinical studies.
Active immunotherapy candidates targeting phosphorylated Tau (clinical-stage)
Liposomal-formulated vaccines designed to elicit antibodies against extracellular phosphorylated Tau species to prevent or reduce Tau spreading in early Alzheimer's disease.
Monoclonal antibody programs targeting pathological proteins (clinical-stage)
Humanized monoclonal antibodies developed to target pathological protein species (e.g., Tau, amyloid-beta, alpha-synuclein) with clinical evaluation of target engagement and PK/PD.
PET imaging tracers for Tau, alpha-synuclein and TDP-43 (diagnostic tracers)
Radiotracer discovery and validation programs producing PET ligands for detection and differentiation of pathological protein aggregates to support diagnosis and biomarker-driven trials.
CNS-optimized small-molecule candidates (aggregation inhibitors)
Small-molecule therapeutics discovered from CNS-focused libraries and optimized for brain penetration and activity against intracellular or extracellular pathological aggregates.
Active immunotherapy candidates targeting alpha-synuclein (clinical-stage)
Optimized vaccine formulations designed to generate robust and boostable antibody responses against pathological alpha-synuclein oligomers for Parkinsonian synucleinopathies.
Active immunotherapy candidates targeting amyloid-beta (clinical-stage)
Liposomal vaccine-type active immunotherapies designed to induce antibodies against pathological amyloid-beta species for prevention or treatment of Alzheimer’s disease, evaluated in early clinical studies.
Active immunotherapy candidates targeting phosphorylated Tau (clinical-stage)
Liposomal-formulated vaccines designed to elicit antibodies against extracellular phosphorylated Tau species to prevent or reduce Tau spreading in early Alzheimer's disease.
Monoclonal antibody programs targeting pathological proteins (clinical-stage)
Humanized monoclonal antibodies developed to target pathological protein species (e.g., Tau, amyloid-beta, alpha-synuclein) with clinical evaluation of target engagement and PK/PD.
PET imaging tracers for Tau, alpha-synuclein and TDP-43 (diagnostic tracers)
Radiotracer discovery and validation programs producing PET ligands for detection and differentiation of pathological protein aggregates to support diagnosis and biomarker-driven trials.
CNS-optimized small-molecule candidates (aggregation inhibitors)
Small-molecule therapeutics discovered from CNS-focused libraries and optimized for brain penetration and activity against intracellular or extracellular pathological aggregates.
Active immunotherapy candidates targeting alpha-synuclein (clinical-stage)
Optimized vaccine formulations designed to generate robust and boostable antibody responses against pathological alpha-synuclein oligomers for Parkinsonian synucleinopathies.
Services
Design and conduct of Phase 1–3 randomized and adaptive clinical trials for therapeutics and diagnostics incorporating imaging, biomarker and immunogenicity endpoints.
Lead discovery and ranking services using assay suites, translational models and CNS-focused chemical libraries to identify and advance therapeutic and diagnostic candidates.
Design, radiochemistry and clinical validation of PET tracers for pathological protein targets to support diagnosis, differential diagnosis and biomarker-based clinical trials.
Structuring and managing strategic collaborations, licensing and out-licensing to accelerate development, access external resources and monetize assets.
Supplier registration, approved-supplier database onboarding and purchase-order-driven procure-to-pay controls for vendors and CRO/CDMO partners.
Regulatory strategy development, submission planning and quality systems oversight to progress candidates from early phases towards potential commercialization.
Design and conduct of Phase 1–3 randomized and adaptive clinical trials for therapeutics and diagnostics incorporating imaging, biomarker and immunogenicity endpoints.
Lead discovery and ranking services using assay suites, translational models and CNS-focused chemical libraries to identify and advance therapeutic and diagnostic candidates.
Design, radiochemistry and clinical validation of PET tracers for pathological protein targets to support diagnosis, differential diagnosis and biomarker-based clinical trials.
Structuring and managing strategic collaborations, licensing and out-licensing to accelerate development, access external resources and monetize assets.
Supplier registration, approved-supplier database onboarding and purchase-order-driven procure-to-pay controls for vendors and CRO/CDMO partners.
Regulatory strategy development, submission planning and quality systems oversight to progress candidates from early phases towards potential commercialization.
Expertise Areas
- Precision medicine for neurodegenerative diseases
- Biomarker-driven adaptive clinical trial design
- PET radiotracer discovery and validation for neurodegenerative targets
- Active immunotherapy and vaccine development for CNS targets
Key Technologies
- Liposome-anchored peptide vaccine platforms
- PET radiochemistry and tracer development
- CNS-optimized small-molecule medicinal chemistry
- Monoclonal antibody generation and sequence optimization
News & Updates
Read our latest announcement.
Read our latest announcement.
Preclinical results of our wholly owned anti-Abeta vaccine program ACI-24 show that the optimized formulation generates a potent and sustained immune response. Antibodies showed binding to pyroglutamate Abeta, a highly neurotoxic form of Abeta, which, following recent proof-of-concept from a monoclonal antibody, is a promising target for Alzheimer therapy.
Read our latest announcement.
Read our latest announcement.
Preclinical results of our wholly owned anti-Abeta vaccine program ACI-24 show that the optimized formulation generates a potent and sustained immune response. Antibodies showed binding to pyroglutamate Abeta, a highly neurotoxic form of Abeta, which, following recent proof-of-concept from a monoclonal antibody, is a promising target for Alzheimer therapy.